Format

Send to

Choose Destination
Nutrients. 2018 Nov 14;10(11). pii: E1756. doi: 10.3390/nu10111756.

Experimental Evidence of the Antitumor, Antimetastatic and Antiangiogenic Activity of Ellagic Acid.

Author information

1
Department of Systems Medicine, University of Rome Tor Vergata, 00173 Rome, Italy. claudiaceci@hotmail.it.
2
Laboratory of Molecular Oncology, Istituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167 Rome, Italy. p.lacal@idi.it.
3
Department of Systems Medicine, University of Rome Tor Vergata, 00173 Rome, Italy. tentori@uniroma2.it.
4
Laboratory of Medicinal Chemistry, Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00173 Rome, Italy. maria.gabriella.de.martino@uniroma2.it.
5
Urology Unit, Department of Surgical Sciences, University of Rome Tor Vergata, 00173 Rome, Italy. mianor@virgilio.it.
6
Department of Systems Medicine, University of Rome Tor Vergata, 00173 Rome, Italy. graziani@uniroma2.it.

Abstract

Ellagic acid (EA) is a naturally occurring polyphenolic compound endowed with strong antioxidant and anticancer properties that is present in high quantity in a variety of berries, pomegranates, and dried fruits. The antitumor activity of EA has been mostly attributed to direct antiproliferative and apoptotic effects. Moreover, EA can inhibit tumour cell migration, extra-cellular matrix invasion and angiogenesis, all processes that are crucial for tumour infiltrative behaviour and the metastatic process. In addition, EA may increase tumour sensitivity to chemotherapy and radiotherapy. The aim of this review is to summarize the in vitro and in vivo experimental evidence supporting the anticancer activity of pure EA, its metabolites, and EA-containing fruit juice or extracts in a variety of solid tumour models. The EA oral administration as supportive therapy to standard chemotherapy has been recently evaluated in small clinical studies with colorectal or prostate cancer patients. Novel formulations with improved solubility and bioavailability are expected to fully develop the therapeutic potential of EA derivatives in the near future.

KEYWORDS:

angiogenesis; bladder cancer; breast cancer; colorectal cancer; melanoma; metastases; non-small cell lung cancer (NSCLC); ovarian cancer; polyphenolic compounds; prostate cancer

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center